title: Comparison of drug-eluting and bare-metal stents for stable coronary artery disease.
abstract: OBJECTIVE
  The current study was designed to determine whether drug-eluting stents (DES) are superior to bare-metal stents (BMS) in patients with stable angina.
  
  
  BACKGROUND
  Percutaneous coronary intervention has been shown to decrease symptoms of angina; its use for stable angina has not been shown to reduce myocardial infarction or mortality.
  
  
  METHODS
  We conducted a retrospective, cross-sectional analysis of prospective data comparing the use of BMS versus DES in patients who met criteria used by the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) study investigators. The primary outcome was a composite of death, myocardial infarction, stroke, and revascularization on follow-up.
  
  
  RESULTS
  The 1-year primary event rate was 15% in the DES group (95% confidence interval [CI]: 11% to 18%), compared with 27% in the BMS group (95% CI: 23% to 31%, p < 0.001). A Cox proportional hazard regression model was used to adjust for differences in patient characteristics and showed a 1-year DES hazard ratio of 0.51 (95% CI: 0.36 to 0.71, p < 0.001). After 1 year, event rates for the primary outcome increased in DES subjects relative to BMS patients, such that longer follow-up analyses resulted in nonsignificant comparisons.
  
  
  CONCLUSIONS
  These results suggest that the use of DES for patients with stable coronary disease is superior to BMS for 1 year, but that the increment in benefit decreased over continued follow-up. Further research is necessary to identify additional factors to promote longer-term efficacy and safety of DES.
authors.affiliation: Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Horst
authors.forename: Charanjit S
authors.initials: CS
authors.lastname: Rihal
authors.forename: David R
authors.initials: DR
authors.lastname: Holmes
authors.forename: John F
authors.initials: JF
authors.lastname: Bresnahan
authors.forename: Abhiram
authors.initials: A
authors.lastname: Prasad
authors.forename: Gerald
authors.initials: G
authors.lastname: Gau
authors.forename: Ryan
authors.initials: R
authors.lastname: Lennon
authors.forename: Amir
authors.initials: A
authors.lastname: Lerman
mesh_terms: D000368:Aged; D000787:Angina Pectoris / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D003324:Coronary Artery Disease / Q000150:complications / Q000401:mortality / Q000628:therapy*; D003430:Cross-Sectional Studies; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008670:Metals; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D016016:Proportional Hazards Models; D011474:Prosthesis Design; D012189:Retrospective Studies; D018570:Risk Assessment; D015607:Stents; D020521:Stroke / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D008670:Metals